ESAB Debuts its First Battery-Powered Welding Machine
18.11.2022 23:35:00 EET | Business Wire | Press release
Today ESAB, part of ESAB Corporation (NYSE: ESAB), and a world leader in welding and cutting equipment and consumables, unveiled the industry-changing Renegade VOLT™ ES 200i Stick/TIG battery-powered welding system as it closed out SparkWeek, the brand’s week-long, virtual launch event highlighting new welding and fabrication products, automation and robotics solutions, and industry-shaping PPE.
Developed in conjunction with Stanley Black & Decker and powered by four DEWALT® FLEXVOLT® 12 Ah (amp-hour) batteries, the Renegade VOLT marks a crossroads for the welding industry, as ESAB establishes a new product category. For the first-time welders have a battery-powered welding machine which operates on interchangeable, rechargeable power tool batteries. The VOLT is a highly portable option for off-the-grid welding across key industries like maintenance and repair, construction, shipyard, rail, power generation, offshore and farm/agriculture. The product will be available for purchase in Q1 2023.
"ESAB has continuously brought new ideas to the market since the invention of the first coated welding electrode more than a century ago. With the Renegade VOLT, we have taken the idea of portability and supercharged it,” said Olivier Biebuyck, President, EMEA and Global Products, ESAB Corporation. “Up until now, welding jobs have only gone as far as the equipment could reach. Welders were stuck lugging around heavy leads, tripping over cables, and wondering what kind of power would be at the job site. Sometimes welders even spent more time on job set up and breakdown than welding. Today, ESAB eliminated those constraints and ushered in a new age. This is the age of true welding freedom. No cords and heavy leads, no time-consuming setup, no engines, or fuel."
The VOLT launch capped off a string of new and re-imagined solutions from ESAB which were unveiled during SparkWeek. The company made more than 15 announcements between Monday, November 14 and Friday, November 18 via dynamic, live video premieres at ESAB.com/SparkWeek. The event page now features information about these new products and partnerships, including key specifications and availability information:
- Ruffian 150, ESAB’s all-new engine-driven welder
- Rogue EM and Rogue EMP, MIG and multi-process machines
- Rustler, a completely new ESAB line of compact MIG machines
- Renegade 1 Ph DC, powerful-yet-lightweight machine now in single-phase power
- Warrior EDGE CX System with RobustFeed Edge CX and Exeor torch, a next-generation pulse-MIG power source, feeder, and torch product family
- Sentinel A60, the next iteration of ESAB’s industry-leading automatic welding helmet
- Swarm A10, A20, and A30, affordable, performance driven welding helmet portfolio
- Vision T6, easy-to-use CNC cutting machine controller
- Marathon Pac Ultra, a new 1,100-lb. bulk welding wire drum package
- Cutmaster 30+, next-generation manual plasma cutter focused on power and portability
- Thermal Dynamics Automation UC Series, a high precision mechanized plasma system
- Victor Edge 2.0 Phase IV and HRF2400, gas regulator and a regulator/flowmeter combination
- Versotrac Cadet, a compact, efficient, and easy to use submerged arc welding (SAW) tractor
- InduSuite, advanced software that connects welding and cutting data, machinery, and processes across one platform
- PURUS, new and improved premium wire specially formulated to reduce post-weld cleaning
ESAB products are available globally for purchase through select distributors and retail locations. Visit ESAB.com to find a local distributor and learn more about the product portfolio.
About ESAB
ESAB is a world leader in fabrication technology. For more than 100 years ESAB has transformed industries built by fabricators, providing complete workflow solutions through our diverse portfolio of products from more than 40 of the most trusted brands in welding and cutting in the world. From industrial demands to repair and maintenance, innovators that shape the world, rely on ESAB’s portfolio. To learn more, visit ESAB.com.
About ESAB Corporation
ESAB Corporation (NYSE: ESAB) is a world leader in fabrication and gas control technology, providing our partners with advanced equipment, consumables, gas control equipment, robotics, and digital solutions which enable the everyday and extraordinary work that shapes our world. To learn more, visit ESABcorporation.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005574/en/
Contact information
Media Contact for ESAB
Tilea Coleman
Vice President, Corporate Communications
E-mail: mediarelations@esab.com
Phone: 1-301-323-9092
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 13:45:00 EET | Press release
TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its dealer network, aftersales capabilities and customer support infrastructure across key markets. In Italy, its first European market, TVS now works with around 100 dealers. Retail sales in Italy are up 110% this year to Septem
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom